Intervention with concentrated albumin for resuscitation of undifferentiated sepsis (ICARUS): a randomised controlled trial

Grant ID: EMLE-144R33-2020-WILLIAMS

Project Summary

Global estimates suggest that approximately 5 million people die from infection each year. Research into improved management and treatment for patients with infection is essential for reducing mortality.

Patients presenting to the emergency department with severe infections are treated with fluids in the vein to maintain optimal blood volume, to keep the heart working properly and tissues well oxygenated. Fluids administered to patients include crystalloids (water-based fluids that include salts and other water-soluble molecules), and albumin (a fluid manufactured from human plasma). Crystalloids are most commonly used by emergency physicians in standard care however initial evidence indicates that albumin may result in better outcomes for patients with severe infections, but further quality trials are required for validation.

In this study, researchers will randomise emergency department patients with severe infection to receive either albumin or crystalloids. The aim of the study is to provide emergency doctors with important information about how to best treat patients with infections to improve blood pressure, prevent organ failure, reduce the need for intensive care and potentially reduce the number of deaths.

---

Dissemination

Presentation:

- Williams, J., Intervention with concentrated albumin for resuscitation of undifferentiated sepsis – the ICARUS pilot trial (oral presentation). ICEM Melbourne, June 2022.

---

SHARE